{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:49:51Z","timestamp":1779140991473,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>High level of comorbidity between bipolar disorder or schizophrenia and cardiovascular diseases (CVD) in clinical practice may contribute to drug\u2013drug interactions between medications used in these conditions. The aim of this study was to evaluate harmful interactions between antipsychotics and medications used in treatment of CVD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The analysis of 52 cases of adverse reactions with a clinical picture indicates that they were the result of the combination of antipsychotic with cardiovascular medications.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The highest number of interactions with antipsychotics was recorded among beta-blockers (<jats:italic>n<\/jats:italic>\u2009=\u200913, 25% of all cases), including cardiac arrhythmias [atrial fibrillation (<jats:italic>n<\/jats:italic>\u2009=\u20091): risperidone plus atenolol; bradycardia (<jats:italic>n<\/jats:italic>\u2009=\u20091): perphenazine with metoprolol; ventricular arrhythmias: sertindole with metoprolol (<jats:italic>n<\/jats:italic>\u2009=\u20091) and ziprasidone with sotalol (<jats:italic>n<\/jats:italic>\u2009=\u20093)] and hypotension [chlorprotixene with nebivolol or metoprolol (<jats:italic>n<\/jats:italic>\u2009=\u20092)]. 12 cases concerned statins\u2014myalgia, myopathy, or creatine kinase elevation appeared after combination of atorvastatin with haloperidol (<jats:italic>n<\/jats:italic>\u2009=\u20091), quetiapine (<jats:italic>n<\/jats:italic>\u2009=\u20093) or risperidone (<jats:italic>n<\/jats:italic>\u2009=\u20091), and simvastatin with quetiapine (<jats:italic>n<\/jats:italic>\u2009=\u20095) or risperidone (<jats:italic>n<\/jats:italic>\u2009=\u20092). There were also cases of interactions observed for the use of antipsychotics with anti-arrhythmic drugs (amiodarone, flecainide, propafenone) (<jats:italic>n<\/jats:italic>\u2009=\u200911), calcium channel blockers (<jats:italic>n<\/jats:italic>\u2009=\u20096), and other cardiac medications: clonidine, dabigatran, doxazosin, ivabradine, and losartan (<jats:italic>n<\/jats:italic>\u2009=\u200910).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Due to a high risk of interactions and related adverse effects, particular attention should be paid while using cardiovascular medications with antipsychotics. Clinical decisions should be preceded by a detailed analysis of safety, risk\u2013benefit ratio to search for, as safe as possible, drug combinations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s43440-020-00058-6","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T14:08:59Z","timestamp":1583158139000},"page":"350-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1895","authenticated-orcid":false,"given":"Marcin","family":"Siwek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Woro\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Gorostowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Wordliczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"58_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373960-5.00335-X","volume-title":"The global burden of disease: 2004 update","author":"C Mathers","year":"2008","unstructured":"Mathers C, Boerma T, Ma Fat D, World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008."},{"issue":"1","key":"58_CR2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.31887\/DCNS.2018.20.1\/mdehert","volume":"20","author":"M De Hert","year":"2018","unstructured":"De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci. 2018;20(1):31\u201340.","journal-title":"Dialogues Clin Neurosci."},{"issue":"1","key":"58_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"M De Hert","year":"2011","unstructured":"De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52\u201377.","journal-title":"World Psychiatry."},{"issue":"2","key":"58_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163\u201380.","journal-title":"World Psychiatry"},{"issue":"11","key":"58_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jpsychires.2013.07.011","volume":"47","author":"Z Fan","year":"2013","unstructured":"Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47(11):1549\u201356.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"58_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/acps.12408","volume":"131","author":"JF Hayes","year":"2015","unstructured":"Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand. 2015;131(6):417\u201325.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"58_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1399-5618.2009.00735.x","volume":"11","author":"BI Goldstein","year":"2009","unstructured":"Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11(6):657\u201362.","journal-title":"Bipolar Disord"},{"issue":"9","key":"58_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamapsychiatry.2013.1394","volume":"70","author":"C Crump","year":"2013","unstructured":"Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"58_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"issue":"1","key":"58_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1229.104497","volume":"11","author":"S Kukreja","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82\u201399.","journal-title":"Mens Sana Monogr"},{"issue":"1","key":"58_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1472-8206.2009.00757.x","volume":"24","author":"M Volpe","year":"2010","unstructured":"Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24(1):9\u201317.","journal-title":"Fundam Clin Pharmacol"},{"key":"58_CR12","volume-title":"Psychotropic drug directory 2018","author":"S Bazire","year":"2018","unstructured":"Bazire S. Psychotropic drug directory 2018. Dorsington: Lloyd-Reinhold Communications; 2018."},{"issue":"D1","key":"58_CR13","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074\u2013D10821082.","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"58_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.psy.49.3.255","volume":"49","author":"JR Stevens","year":"2008","unstructured":"Stevens JR, Freudenreich O, Stern TA. Elevated clozapine serum level after treatment with amiodarone. Psychosomatics. 2008;49(3):255\u20137.","journal-title":"Psychosomatics"},{"issue":"3","key":"58_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/026988110401800316","volume":"18","author":"MA Webber","year":"2004","unstructured":"Webber MA, Mahmud W, Lightfoot JD, Shekhar A. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol. 2004;18(3):432\u20134.","journal-title":"J Psychopharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-020-00058-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:27:50Z","timestamp":1614644870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-020-00058-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00058-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}